Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | GALR3 | O60755 | 1/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | EPHX1 | P07099 | 3/20 | 0.39 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4344643 | 1.00 | ALDH1A1 (0.48) | ALDH1A1SMN1; SMN2KDM4EGAAGALR3 | |
| SCHEMBL4344632 | 1.00 | ALDH1A1 (0.48) | ALDH1A1SMN1; SMN2KDM4EGAAGALR3 | |
| SCHEMBL4329557 | 0.86 | ALDH1A1 (0.45) | ALDH1A1SMN1; SMN2KDM4EGAASIGMAR1 | |
| SCHEMBL4329569 | 0.86 | ALDH1A1 (0.45) | ALDH1A1SMN1; SMN2KDM4EGAASIGMAR1 | |
| SCHEMBL4329562 | 0.86 | ALDH1A1 (0.45) | ALDH1A1SMN1; SMN2KDM4EGAASIGMAR1 | |
| SCHEMBL4332164 | 0.82 | HTT (0.42) | ALDH1A1SMN1; SMN2KDM4EGAAGALR3 | |
| SCHEMBL4332172 | 0.82 | HTT (0.42) | ALDH1A1SMN1; SMN2KDM4EGAAGALR3 | |
| SCHEMBL4334450 | 0.80 | TYR (0.41) | ALDH1A1SMN1; SMN2SIGMAR1KMT2AMEN1 | |
| SCHEMBL4334453 | 0.80 | TYR (0.41) | ALDH1A1SMN1; SMN2SIGMAR1KMT2AMEN1 | |
| SCHEMBL4334459 | 0.80 | TYR (0.41) | ALDH1A1SMN1; SMN2SIGMAR1KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090285849-A1 | Thiosemicarbazones as anti-virals and immunopotentiators | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2009-11-19 | — | — | US | disclosed |
| US-7521062-B2 | Thiosemicarbazones as anti-virals and immunopotentiators | NOVARTIS VACCINES & DIAGNOSTICS, INC. (US) | 2009-04-21 | — | — | US | disclosed |
| US-20050069555-A1 | Thiosemicarbazones as anti-virals and immunopotentiators | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2005-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090285849-A1 | Thiosemicarbazones as anti-virals and immunopotentiators | MAVS, IRF3, HAVCR2 | ALDH1A1 1459/4885SMN1; SMN2 4740/4885KDM4E 3010/4885 |
| US-20050069555-A1 | Thiosemicarbazones as anti-virals and immunopotentiators | MAVS, IRF3, HAVCR2 | ALDH1A1 1173/4885SMN1; SMN2 4815/4885KDM4E 2338/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.